cmetin2

c-Met-IN-2 is a selective and orally available c-Met inhibitor (IC50: 0.6 nM) exhibiting antitumor activity.

c-Met-IN-21 (compound 54) is a c-Met inhibitor with an IC50 value of 0.45 nM and exhibits antitumor activity in vivo.

c-Met-IN-22 (compound 51am) is an orally active c-Met inhibitor with an IC50 value of 2.54 nM. It exhibits both antiproliferative and antitumor activities and can induce apoptosis.

c-Met-IN-23 (Compound 12g) functions as a c-Met inhibitor with an IC50 of 0.052 μM against c-Met. It also inhibits the MDR1 and MRP1/2 pumps in cancerous HepG2 and BxPC3 cells. As such, c-Met-IN-23 serves as an anticancer agent.

EGFR/c-Met-IN-2 (Compound H-22) is a dual inhibitor of EGFR/c-Met that arrests the G2/M phase to inhibit cell proliferation and demonstrates antitumor activity [1].

c-Met-IN-24 (compound 3g) serves as a dual-target inhibitor for STAT-3 (=4.7 μM) and c-MET (=12.67 μM), exhibiting anticancer properties. It arrests the G2/M cell cycle and induces apoptosis in SNB-75 cells, making it applicable in the research of central nervous system cancers.